FindTrial
Sign In

TAK-755

BIOLOGICAL6 trials

Sponsors

Baxalta now part of Shire, Shire, Takeda

Conditions

Acute Ischemic StrokeSickle Cell DiseaseThrombotic Thrombocytopenic Purpura (TTP)

Phase 1

A Study of SHP655 (rADAMTS13) in Sickle Cell Disease
CompletedNCT03997760
ShireSickle Cell Disease
Start: 2019-10-21End: 2022-10-26Updated: 2024-04-23

Phase 2

A Study of TAK-755 (rADAMTS13) With Little to No Plasma Exchange (PEX) Treatment in Adults With Immune-mediated Thrombotic Thrombocytopenic Purpura (iTTP)
CompletedNCT05714969
TakedaThrombotic Thrombocytopenic Purpura (TTP)
Start: 2023-07-21End: 2026-04-16Updated: 2026-06-17
A Study of TAK-755 in Adults With Acute Ischemic Stroke
RecruitingNCT07392450
TakedaAcute Ischemic Stroke
Start: 2026-05-17End: 2027-12-06Target: 222Updated: 2026-08-14

Phase 3

A Study of BAX 930 in Children, Teenagers, and Adults Born With Thrombotic Thrombocytopenic Purpura (TTP)
CompletedNCT03393975
Baxalta now part of ShireThrombotic Thrombocytopenic Purpura (TTP)
Start: 2017-10-13End: 2024-05-30Updated: 2026-02-09
A Study of TAK-755 in Participants With Congenital Thrombotic Thrombocytopenic Purpura
Active, not recruitingNCT04683003
TakedaThrombotic Thrombocytopenic Purpura (TTP)
Start: 2021-04-14End: 2027-03-16Target: 77Updated: 2026-04-02

Unknown Phase

Expanded Access Program of TAK-755 for Congenital Thrombotic Thrombocytopenic Purpura (cTTP)
NCT05770219
TakedaThrombotic Thrombocytopenic Purpura (TTP)
Updated: 2025-02-24

Related Papers

Recombinant ADAMTS13 in congenital thrombotic thrombocytopenic purpura: final analysis from a randomized phase 3 trial.
2026-09-11
Natural History and Treatment Outcomes of Congenital Thrombotic Thrombocytopenic Purpura: A Retrospective Longitudinal Cohort Study
Journal of health economics and outcomes research2026-08-12
Natural History and Treatment Outcomes of Congenital Thrombotic Thrombocytopenic Purpura: A Retrospective Longitudinal Cohort Study
Journal of health economics and outcomes research2026-08-12
Recombinant ADAMTS13 prophylaxis in patients with congenital thrombotic thrombocytopenic purpura: Final analysis from A phase 3 randomized, controlled study
Blood2025-11-03
Quantitative Systems Pharmacology Modeling of Platelet Responses to Recombinant <scp>ADAMTS13</scp> in Patients With Congenital Thrombotic Thrombocytopenic Purpura
CPT Pharmacometrics & Systems Pharmacology2025-07-041 citations
Mutation Analysis of the <i>ADAMTS13</i> Gene in Patients with Congenital Thrombotic Thrombocytopenic Purpura from the rADAMTS13 Phase 3 Study
Blood2024-11-05
Pharmacodynamic Activity of Recombinant ADAMTS13 Versus Plasma-Based Therapies in Congenital Thrombotic Thrombocytopenic Purpura: Interim Results of a Phase 3 Randomized, Controlled, Open-Label Study
Blood2024-11-05
Recombinant ADAMTS13 Prophylaxis in Pediatric Patients with Congenital Thrombotic Thrombocytopenic Purpura: Results from the Phase 3 Randomized, Crossover Study and the Phase 3b Continuation Study
Blood2024-11-05
Recombinant ADAMTS13 in Congenital Thrombotic Thrombocytopenic Purpura
New England Journal of Medicine2024-05-0166 citations
Recombinant ADAMTS13 for the Treatment of Acute TTP Events in Patients with Congenital Thrombotic Thrombocytopenic Purpura: Results from the Phase 3 Randomized, Controlled, Crossover Study and the Phase 3b Continuation Study
Blood2023-11-029 citations
Safety and Pharmacokinetics of Recombinant ADAMTS13 in Patients with Sickle Cell Disease: A Phase 1 Randomized, Double-Blind, Placebo-Controlled Study
Blood2023-11-023 citations
Population Pharmacokinetics and Exposure-Response Analyses to Demonstrate the Link of Causality between ADAMTS13 and the Clinical Effects of Recombinant ADAMTS13 Compared to Plasma-Based Therapies
Blood2023-11-022 citations
Quantitative System Pharmacology Modeling of the Effect of Recombinant ADAMTS13 on Platelets in Patients with Congenital Thrombotic Thrombocytopenic Purpura
Blood2023-11-02
OC 14.5 Plasma Exchange-free Management of Immune Thrombotic Thrombocytopenic Purpura: The Austrian-German Experience
Research and Practice in Thrombosis and Haemostasis2023-10-01
Recombinant ADAMTS13 for Patients with Severe Congenital Thrombotic Thrombocytopenic Purpura: Design of a Phase 3b Open-Label Continuation Study of Prophylactic and on-Demand Treatment
Blood2021-11-058 citations
Recombinant ADAMTS13 for Patients with Sickle Cell Disease: Design of a Phase 1 Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study
Blood2021-11-053 citations